| [1] |
Ngo L, Hee SW, Lim LC, et al.
Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab[J]. Leuk LymphomaLeuk Lymphoma, 2008, 49(3): 462-469.
doi: 10.1080/10428190701809156 |
| [2] |
Barrington SF, Johnson PWM.
18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?[J]. J Nucl MedJ Nucl Med, 2017, 58(10): 1539-1544.
doi: 10.2967/jnumed.116.181347 |
| [3] |
Zhang XY, Song L, Wang PJ, et al.
Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax[J]. Acta HaematolActa Haematol, 2019, 5: 1-7.
doi: 10.1159/000500512 |
| [4] |
Winter A, Rybicki L, Shah SN, et al.
Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation[J]. Leuk LymphomaLeuk Lymphoma, 2018, 59(5): 1195-1201.
doi: 10.1080/10428194.2017.1369065 |
| [5] |
Schöder H, Zelenetz AD, Hamlin P, et al.
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma[J]. J Nucl MedJ Nucl Med, 2016, 57(5): 728-734.
doi: 10.2967/jnumed.115.166769 |
| [6] |
Safar V, Dupuis J, Itti E, et al.
Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab[J]. J Clin OncolJ Clin Oncol, 2012, 30(2): 184-190.
doi: 10.1200/JCO.2011.38.2648 |
| [7] |
Pregno P, Chiappella A, Bellò M, et al.
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP[J]. BloodBlood, 2012, 119(9): 2066-2073.
doi: 10.1182/blood-2011-06-359943 |
| [8] |
Kim J, Song YS, Lee JS, et al.
Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores[J]. Leuk LymphomaLeuk Lymphoma, 2018, 59(2): 340-347.
doi: 10.1080/10428194.2017.1339877 |
| [9] |
Itti E, Meignan M, Berriolo-Riedinger A, et al.
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2013, 40(9): 1312-1320.
doi: 10.1007/s00259-013-2435-6 |
| [10] |
Nols N, Mounier N, Bouazza S, et al.
Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma[J]. Leuk LymphomaLeuk Lymphoma, 2014, 55(4): 773-780.
doi: 10.3109/10428194.2013.831848 |
| [11] |
范洋, 张玥伟, 杨志, 等.
化疗早期18F-FDGPET/CT评价弥漫性大B细胞淋巴瘤的疗效及预后预测[J]. 肿瘤肿瘤, 2015, 35(9): 1013-1020.
doi: 10.3781/j.issn.1000-7431.2015.33.254 Fan Y, Zhang YW, Yang Z, et al. Early 18F-FDG PET/CT in evaluation of chemotherapeutic response and prognostic prediction for patients with diffuse large B-cell lymphoma[J]. TumorTumor, 2015, 35(9): 1013-1020. doi: 10.3781/j.issn.1000-7431.2015.33.254 |
| [12] |
Zhang YY, Song L, Zhao MX, et al.
A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUVmax[J]. Cancer MedCancer Med, 2019, 8(11): 5137-5147.
doi: 10.1002/cam4.2284 |
| [13] |
Li X, Sun X, Li J, et al.
Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma[J]. Cancer MedCancer Med, 2019, 8(11): 5012-5022.
doi: 10.1002/cam4.2404 |
| [14] |
Mikhaeel NG, Smith D, Dunn JT, et al.
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2016, 43(7): 1209-1219.
doi: 10.1007/s00259-016-3315-7 |
| [15] |
Song MK, Yang DH, Lee GW, et al.
High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era[J]. Leuk ResLeuk Res, 2016, 42: 1-6.
doi: 10.1016/j.leukres.2016.01.010 |
| [16] |
Gallicchio R, Mansueto G, Simeon V, et al.
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J HaematolEur J Haematol, 2014, 92(5): 382-389.
doi: 10.1111/ejh.12268 |
| [17] |
辛仲宏, 张皓.
18F-FDG PET/CT肿瘤代谢负荷参数评估恶性肿瘤预后的价值[J]. 国际医学放射学杂志国际医学放射学杂志, 2018, 41(4): 459-463.
doi: 10.19300/j.2018.Z5140 Xin ZH, Zhang H. Prognostic value of metabolic tumor burden parameters on 18F-FDG PET/CT in malignant tumor[J]. Int J Med RadiolInt J Med Radiol, 2018, 41(4): 459-463. doi: 10.19300/j.2018.Z5140 |
| [18] |
Freudenberg LS, Antoch G, Schütt P, et al.
FDG-PET/CT in re-staging of patients with lymphoma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2004, 31(3): 325-329.
doi: 10.1007/s00259-003-1375-y |
| [19] |
Zhou MG, Chen YM, Huang HH, et al. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma[J/OL]. Oncotarget, 2016, 7(50): 83544−83553 [2019-01-03]. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13180&path[]=41778. DOI: 10.18632/oncotarget.13180. |
| [20] |
Sasanelli M, Meignan M, Haioun C, et al.
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2014, 41(11): 2017-2022.
doi: 10.1007/s00259-014-2822-7 |
| [21] |
Alizadeh AA, Eisen MB, Davis RE, et al.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J]. NatureNature, 2000, 403(6769): 503-511.
doi: 10.1038/35000501 |
| [22] |
Toledano MN, Desbordes P, Banjar A, et al.
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(5): 680-688.
doi: 10.1007/s00259-017-3907-x |
| [23] |
Kwon SH, Kang DR, Kim J, et al.
Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma[J]. Clin RadiolClin Radiol, 2016, 71(3): 280-286.
doi: 10.1016/j.crad.2015.11.019 |
| [24] |
de Oliveira Costa R, Hallack Neto A, Siqueira S, et al.
Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era[J]. Nucl Med CommunNucl Med Commun, 2016, 37(10): 1095-1101.
doi: 10.1097/MNM.0000000000000553 |
| [25] |
Kim J, Lee JO, Paik JH, et al.
Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma[J]. Ann Nucl MedAnn Nucl Med, 2017, 31(1): 1-11.
doi: 10.1007/s12149-016-1123-6 |
| [26] |
Jiang MQ, Chen P, Ruan XZ, et al.
Interim 18F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era[J]. Nucl Med CommunNucl Med Commun, 2018, 39(2): 147-153.
doi: 10.1097/MNM.0000000000000784 |
| [27] |
Minamimoto R, Fayad L, Advani R, et al.
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring[J]. RadiologyRadiology, 2016, 280(1): 220-229.
doi: 10.1148/radiol.2015150689 |
| [28] |
Kong Y, Qu LL, Li YK, et al.
Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings[J]. Medicine (Baltimore)Medicine (Baltimore), 2016, 95(6): e2808-.
doi: 10.1097/MD.0000000000002808 |
| [29] |
Liu T, Chen L, Pan J, et al.
Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography[J]. Acta HaematolActa Haematol, 2018, 139(3): 148-157.
doi: 10.1159/000479486 |
| [30] |
Fan Y, Zhang YW, Yang Z, et al.
Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma[J]. Leuk LymphomaLeuk Lymphoma, 2017, 58(9): 2065-2073.
doi: 10.1080/10428194.2016.1277384 |
| [31] |
Itti E, Juweid ME, Haioun C, et al.
Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background[J]. J Nucl MedJ Nucl Med, 2010, 51(12): 1857-1862.
doi: 10.2967/jnumed.110.080556 |